Eli Lilly (NYSE: LLY) CEO Highlights India's Biotech Funding Gap
David Ricks sees scientific potential, while arguing that discovery research needs a stronger financing environment.
Get analysis like this in your inbox.
Join investors and analysts following Lex Commentary.
Lilly chief executive David Ricks has pointed to India's scientific talent and manufacturing expertise while identifying research funding as a constraint on its innovative biotechnology sector. His comments appeared in an Economic Times interview published on 2 October.
Ricks said Lilly was open to discussions with Indian biotechnology companies about partnerships. He contrasted the country's capabilities with a less developed financing environment for discovery research and related activities.
This is an expression of strategic interest, rather than an announced licensing agreement or investment commitment. Its importance lies in the conditions that could make future collaborations possible.
Scientific talent alone does not supply the capital needed to move an idea through experimental validation and clinical development. A stronger funding environment could give more local companies assets mature enough to attract international partners. Equally, interest from a large pharmaceutical company cannot substitute for that domestic infrastructure. For India's innovation ambitions, the interview directs attention towards the financing and development stages between laboratory capability and a commercially negotiable medicine.